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Background
As mortality of HIV+ patients has dramatically declined
following the introduction of HAART, chronic liver dis-
ease has become one of the leading causes of death in this
population. While HIV infection worsens the progression
of liver fibrosis in HIV/HCV co-infected persons, the bal-
ance between the benefits of antiretrovirals and the dele-
terious consequences of antiretroviral-associated liver
toxicity are still controversial.
Methods
A cohort of HIV cirrhotic patients was followed-up from
October 2004 to June 2008 at one large HIV clinic.
Asymptomatic cirrhotic patients were identified using
transient elastometry (FibroScan). Median elastometric
values >14 Kpascals were considered for liver cirrhosis, as
previously showing 97% correlation with liver biopsy.
Summary of results
A total of 178 HIV+ cirrhotic patients were identified.
Main baseline characteristics: mean age 45 years, 72%
male, IDUs 81%, 80% under HAART. Etiology of liver cir-
rhosis: 87% chronic hepatitis C, 23% alcohol abuse, 10%
chronic hepatitis B, 4% cryptogenic hepatitis, 3% hepati-
tis delta, and 7% multiple viral hepatitis. During a median
follow-up of 4 years, 26 (15%) patients were lost to fol-
low-up, 11 (7%) died (eight from liver decompensation,
two from liver cancer, and three from other causes). Mod-
erate to severe hepatic dysfunction (Child B or C) was
diagnosed in 13% of patients at the end of follow-up.
Mean liver stiffness was 25 kPa at baseline and 28 kPa at
the end of follow-up. Mean aminotransferase levels (AST/
ALT) decreased from 76/74 to 64/62 IU/L. After successful
therapy, six patients cleared HCV.
Conclusion
Liver cirrhosis in HIV+ patients under HAART does not
seem to progress as fast as expected without antiretroviral
therapy. This observation may be due to multiple factors,
such as appropriate prevention of variceal bleeding and
liver cancer following diagnosis of compensated cirrhosis
using FibroScan, successful treatment of chronic hepatitis
C, and selection of less hepatotoxic drugs in this popula-
tion.
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